跳转至内容
Merck
CN
  • Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets.

Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets.

Biochemical pharmacology (2020-02-18)
Tariq Fellous, Fabrizia De Maio, Hilal Kalkan, Biagio Carannante, Serena Boccella, Stefania Petrosino, Sabatino Maione, Vincenzo Di Marzo, Fabio Arturo Iannotti
摘要

The cellular microenvironment plays a critical role in the maintenance of bone marrow-derived mesenchymal stem cells (BM-MSCs) and their subsequent cell lineage differentiation. Recent studies suggested that individuals with adipocyte-related metabolic disorders have altered function and adipogenic potential of adipose stem cell subpopulations, primarily BM-MSCs, increasing the risk of heart attack, stroke or diabetes. In this study, we explored the potential therapeutic effect of some of the most abundant non-euphoric compounds derived from the Cannabis sativa plant (or phytocannabinoids) including tetrahydrocannabivarin (THCV), cannabidiol (CBD), cannabigerol (CBG), cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA), by analysing their pharmacological activity on viability of endogenous BM-MSCs as well as their ability to alter BM-MSC proliferation and differentiation into mature adipocytes. We provide evidence that CBD, CBDA, CBGA and THCV (5 µM) increase the number of viable BM-MSCs; whereas only CBG (5 µM) and CBD (5 µM) alone or in combination promote BM-MSCs maturation into adipocytes via distinct molecular mechanisms. These effects were revealed both in vitro and in vivo. In addition, phytocannabinoids prevented the insulin signalling impairment induced by palmitate in adipocytes differentiated from BM-MSCs. Our study highlights phytocannabinoids as a potential novel pharmacological tool to regain control of functional adipose tissue in unregulated energy homeostasis often occurring in metabolic disorders including type 2 diabetes mellitus (T2DM), aging and lipodystrophy.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
Protease Inhibitor Cocktail, for use with mammalian cell and tissue extracts, DMSO solution
Sigma-Aldrich
TWEEN ® 20, viscous liquid
Sigma-Aldrich
磷酸酶抑制剂混合物2, aqueous solution (dark coloration may develop upon storage, which does not affect the activity)
Sigma-Aldrich
胰岛素 来源于牛胰腺, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, BioUltra, ≥99%
Sigma-Aldrich
聚乙二醇12羟基硬脂酸酯
Sigma-Aldrich
罗格列酮, ≥98% (HPLC)
Sigma-Aldrich
吲哚美辛, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
AM251, >98% (HPLC), solid
Sigma-Aldrich
AM630, ≥90% (HPLC)
Sigma-Aldrich
TWEEN ® 20, viscous liquid
Sigma-Aldrich
GW7647, ≥98% (HPLC)